Global Locator
Genzyme Websites
Health Care Professionals
Company
Products
Research
Patients
Responsibility
Careers
News
About Genzyme
Company Leadership
Business Units
News
Press Contacts
Subscribe to News
Recognition and Awards
Working With Genzyme
Global Reach
Download Genzyme Materials
Today is September 19, 2024. All times in Eastern Daylight Time.
Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials
10/08/2015 - 01:00 AM
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis
10/07/2015 - 03:00 AM
Genzyme Introduces “vs.MS,” a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better Informed Care
10/05/2015 - 09:00 AM
Alnylam and Genzyme Announce that Genzyme Opts into ALN-AT3 Hemophilia Program for Development and Commercialization Outside of North America and Western Europe
10/01/2015 - 07:00 AM
More Than 50 Presentations of New Data from Genzyme’s Multiple Sclerosis Franchise to be Featured at ECTRIMS
09/23/2015 - 07:00 AM
Genzyme Launches Fifth Annual Patient Advocacy Leadership (PAL) Awards Program
07/29/2015 - 08:00 AM
Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa® (vandetanib) from AstraZeneca
07/27/2015 - 02:00 AM
Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients
06/15/2015 - 08:00 AM
FDA Grants Breakthrough Therapy Designation for Genzyme’s Olipudase Alfa
06/04/2015 - 01:00 AM
Genzyme Commemorates World MS Day with Awareness and Educational Events Globally
05/27/2015 - 06:00 AM
Genzyme to Present Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) Data at CMSC
05/26/2015 - 08:00 AM
Genzyme’s Announces Launch of Expression of Hope III Art Exhibit
05/20/2015 - 07:00 AM
Genzyme Receives Innovation Award from the National Organization for Rare Disorders (NORD) for the Development of Cerdelga®
05/19/2015 - 08:00 AM
FDA Grants Fast Track Designation to Genzyme’s Investigational Substrate Reduction Therapy for the Treatment of Fabry Disease
04/28/2015 - 01:00 AM
Effect of Genzyme’s Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Years
04/23/2015 - 09:00 AM
Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease
04/21/2015 - 09:00 AM
Genzyme to Present New Long-Term Data on Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) at AAN
04/13/2015 - 09:00 AM
Genzyme’s Cerdelga® (eliglustat) Capsules Approved in Japan
03/30/2015 - 11:00 AM
Genzyme Convenes Sixth Annual Gaucher Leadership Forum
03/26/2015 - 01:30 PM
ENCORE Clinical Data Published in The Lancet Suggest Treatment with Oral Maintenance Therapy Effective in Previously Treated Gaucher Disease Patients
03/25/2015 - 09:12 PM
Genzyme Recognizes International Rare Disease Day with Global Education and Fund-Raising Events; Announces Founding Partnership of Give RARE
02/27/2015 - 08:00 AM
ENGAGE Randomized Clinical Trial Evaluating Cerdelga® (eliglustat) for Treatment-Naïve Patients with Gaucher Disease Type 1 Published in The Journal of the American Medical Association
02/17/2015 - 11:31 AM
Genzyme Presents Data from its Phase 1b Program for Niemann-Pick Type B at the Lysosomal Disease Network’s WORLD Symposium 2015
02/12/2015 - 04:15 PM
Genzyme Presents Phase 3 Clinical Trial Extension Results for Cerdelga® (eliglustat) at Lysosomal Disease Network’s WORLD Symposium 2015
02/12/2015 - 08:45 AM
European Commission Grants Marketing Authorization for Cerdelga® (eliglustat), Genzyme’s Oral Therapy for Gaucher Disease Type 1
01/22/2015 - 01:00 AM
1
2
3
4
5
6
7
8
9
10
11
12
« Previous
Next »
infoBox
LinkedIn
Yahoo! Buzz
Facebook
Twitter
Delicious
DIGG